Welcome to our dedicated page for Bon Natural Life SEC filings (Ticker: BON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bon Natural Life Limited (NASDAQ: BON) files as a foreign private issuer with the U.S. Securities and Exchange Commission, providing investors with detailed information on its operations in the natural, health, and personal care industries. As a Cayman Islands company with principal offices in Xi’an, China, Bon uses Form 20-F for annual reporting and Form 6-K for interim and current disclosures.
On this page, you can review Bon’s Form 6-K current reports, which often include unaudited interim financial results, Sales Cooperation Agreements, and corporate updates. For example, recent 6-K filings describe how Bon’s subsidiary Xi’an App-Chem Bio (Tech) Co., Ltd. entered into non-exclusive Sales Cooperation Agreements for natural prebiotic series products, natural weight loss products, second-generation tea pigment digestive health products, and second-generation Apple Series metabolic health products, each with specified territories, terms, and guaranteed aggregate sales amounts.
Filings also provide segment-level detail on Bon’s three main product categories: fragrance compounds, health supplements (powder drinks), and bioactive food ingredients. Revenue and cost of revenue are broken out by category, with narrative explanations of changes in sales volumes, market demand, and new product lines integrating Chinese medicine into bioactive food ingredients.
Regulatory and capital markets disclosures appear in Bon’s filings as well. In 2025, multiple Form 6-Ks outline the company’s interactions with the Nasdaq Stock Market regarding minimum bid price compliance and public interest concerns, the subsequent decision by a Nasdaq Hearings Panel to allow continued listing, and the imposition of a one-year Discretionary Panel Monitor. Other filings document corporate actions such as the resignation and appointment of the Chief Financial Officer, along with related employment agreements.
Stock Titan’s interface surfaces these SEC filings with AI-powered summaries that highlight key terms in supply and cooperation agreements, segment performance drivers in interim results, and important listing or governance developments. Users can quickly scan new 6-Ks and 20-Fs, then drill into the full text on EDGAR for deeper analysis, while also monitoring how Bon’s fragrance, prebiotic, tea pigment, and bioactive ingredient businesses are described in official regulatory documents.
Bon Natural Life Ltd director Chen Jing Veronica filed an initial Form 3, which is a required disclosure of insider status and beneficial ownership. This filing reports no stock transactions, and the data provided does not list any derivative positions, making it a routine compliance update.
Bon Natural Life Ltd director and Chief Executive Officer Hu Yongwei filed an initial insider ownership report. The filing shows direct holdings of 2,004,427 Class B ordinary shares and 80,177 Class A ordinary shares. The Class B shares are convertible, at Hu’s discretion, into an aggregate of 80,177 Class A shares under applicable terms.
Bon Natural Life Ltd Chief Operating Officer Xue Yingchun filed an initial ownership report showing indirect holdings of the company’s Class A Ordinary Shares. The filing reports beneficial ownership of 120 Class A Ordinary Shares held through Lavender Oil Limited, reflecting Xue’s proportional ownership interest in that entity.
Bon Natural Life Ltd disclosed that Ma Xin, the company’s Chief Financial Officer, has filed an initial Form 3 as a reporting person. This filing establishes Ma Xin’s status as an officer subject to insider reporting rules but does not report any specific transactions or derivative positions.
Bon Natural Life Ltd filed an initial ownership report for Chief Marketing Officer Wenjuan Chen. The filing shows indirect beneficial ownership of 80 Class A Ordinary Shares, which are held directly by Lavender Oil Limited, an entity in which Chen holds a proportional ownership interest.
Bon Natural Life Ltd director and Chief Technology Officer liu jing filed an initial ownership report showing a significant equity stake. A footnote states that liu jing holds 2,004,427 Class B ordinary shares, which are convertible, at the reporting person's discretion, into an aggregate of 80,177 Class A ordinary shares, subject to applicable terms and conditions. The filing also reports direct ownership of 1,496 Class A ordinary shares, giving investors a view of the CTO’s aligned interest through both high-vote Class B stock and its Class A equivalent.
Bon Natural Life Ltd director Gao Jianjun has filed an initial Form 3, which is the first statement of beneficial ownership as a company insider. The data provided shows no reported purchases, sales, gifts, or derivative exercises, and no current derivative positions listed.
Bon Natural Life Limited reported a leadership change in its technology function. On March 12, 2026, Chief Technology Officer and Chief Scientist Jianli Liu resigned from all positions with immediate effect, with no known disagreements related to the company’s operations, policies or practices.
Effective March 16, 2026, the company appointed Jing Liu, a current director and the wife of controller Hu Yongwei, as Chief Technology Officer. She is a long-time lecturer at Xi’an University of Science and Technology with research in supramolecular chemistry, chemical processes and new energy technologies. Under an employment agreement effective March 16, 2026, she will receive a monthly salary of approximately $1,000.
Bon Natural Life Limited reported that its subsidiary Xi’an App-Chem Bio-Tech Co., Ltd. signed a three-year Framework Cooperation Agreement with Shaanxi Chang’an Pilot Life Science Industry Innovation Center to build an integrated innovation chain from basic research to industrial application.
The partners will co-establish the “BON & Pilot Natural Ingredients and Biomanufacturing Joint Laboratory,” focusing on AI-driven bio-manufacturing of natural active ingredients for functional foods and personal care products, plus a future engineering center for process development and pilot-scale verification. The Agreement also outlines broader strategic cooperation in technology R&D, market expansion, capital partnerships, and potential M&A, and may be terminated by either party with three months’ notice.
Bon Natural Life Limited filed its annual report for the year ended September 30, 2025, showing weaker results as revenue fell to $18,670,684 from $23,844,556 in 2024 and $29,522,353 in 2023. Gross profit declined to $3,878,821, and the company swung to a net loss of $2,049,431 after reporting net income of $345,248 a year earlier.
Total assets increased to $85,185,615 and total equity rose to $57,997,739, while total liabilities grew to $27,187,876. The Cayman holding company operates entirely through PRC subsidiaries, highlights extensive China regulatory and legal risks, HFCAA-related delisting risk, and notes it has never paid dividends and intends to retain earnings to finance expansion.